Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mental Disorders AND Mental Health AND Screening

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    295 result(s) found for: Mental Disorders AND Mental Health AND Screening. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003524-20 Sponsor Protocol Number: BP41316 Start Date*: 2020-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participant...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000757-13 Sponsor Protocol Number: RGH-MD-54 Start Date*: 2016-06-07
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005708-17 Sponsor Protocol Number: ELB139202-05 Start Date*: 2006-03-27
    Sponsor Name:elbion AG
    Full Title: International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d...
    Medical condition: Male and female patients with diagnosis of concurrent panic disorder according to DSM-IV, with or without agoraphobia (DSM IV 300.21 and 300.1) according to Mini International Neuropsychiatric Inte...
    Disease: Version SOC Term Classification Code Term Level
    10037175
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017806-36 Sponsor Protocol Number: CRC287 Start Date*: 2010-11-03
    Sponsor Name:University of Surrey
    Full Title: Effect of Vitano® on physiological and psychological responses to psychological stress assessed under laboratory conditions and in everyday life.
    Medical condition: Psychological stress
    Disease: Version SOC Term Classification Code Term Level
    12 10037175 Stress LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003219-22 Sponsor Protocol Number: LMS/SF/UH/0018 Start Date*: 2014-01-27
    Sponsor Name:Hertfordshire Partnership University NHS Foundation Trust [...]
    1. Hertfordshire Partnership University NHS Foundation Trust
    2. University of Hertfordshire
    Full Title: A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination i...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10037174 Psychiatric disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003989-12 Sponsor Protocol Number: NBI-1065845-MDD2024 Start Date*: 2022-04-06
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000756-98 Sponsor Protocol Number: RGH-MD-53 Start Date*: 2016-07-19
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-004688-30 Sponsor Protocol Number: 15892A Start Date*: 2014-05-19
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care
    Medical condition: Alcohol Dependency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    16.1 10037175 - Psychiatric disorders 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005878-37 Sponsor Protocol Number: 039(C)SC11063 Start Date*: 2012-06-05
    Sponsor Name:ANGELINI
    Full Title: A randomized, double-blind study comparing the efficacy and safety of trazodone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012375 Depressed mood disorders and disturbances HLGT
    14.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    14.1 10037175 - Psychiatric disorders 10012401 Depressive disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-004647-37 Sponsor Protocol Number: G0373 Start Date*: 2006-11-06
    Sponsor Name:Bangor University
    Full Title: Folate Augmentation of Treatment – Evaluation of Depression: a randomised controlled trial
    Medical condition: Individuals with moderate to severe depression according to ICD-10 criteria.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002901-68 Sponsor Protocol Number: Start Date*: 2018-11-19
    Sponsor Name:MAPREG
    Full Title: Double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responde...
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005206-37 Sponsor Protocol Number: CNTO136MDD2001 Start Date*: 2015-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    19.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022638-96 Sponsor Protocol Number: CAFQ056B2214 Start Date*: 2011-06-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FR (Completed) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000251-89 Sponsor Protocol Number: 1042-0800 Start Date*: 2014-10-22
    Sponsor Name:Antwerp University Hospital
    Full Title: A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome
    Medical condition: behavioral problems in children with fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000736-33 Sponsor Protocol Number: CAFQ056X2201 Start Date*: 2017-10-25
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD).
    Medical condition: Cocaine Use Disorder according to DSM 5
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000173266 10009815 Cocaine addiction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000778-71 Sponsor Protocol Number: CN162-007 Start Date*: 2011-11-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depress...
    Medical condition: Subjects with Treatment Resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002542-33 Sponsor Protocol Number: ZYN2-CL-033 Start Date*: 2022-02-22
    Sponsor Name:Zynerba Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro...
    Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004686-26 Sponsor Protocol Number: 0594-020 Start Date*: 2009-07-29
    Sponsor Name:Merck & Co., Inc.
    Full Title: Ensayo clínico multicéntrico, aleatorizado, doble ciego, en fase II y en dos etapas para evaluar la eficacia y la seguridad de MK-0594 en pacientes con alcoholismo. A Phase II Multicenter, Randomi...
    Medical condition: Dependencia Alcohólica Alcohol Dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005318-35 Sponsor Protocol Number: 172009 Start Date*: 2009-01-29
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A prospective, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 25935 in relapse prevention in subjects with alcohol dependence.
    Medical condition: Alcoholism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001639 Alcoholism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002563-27 Sponsor Protocol Number: 12023A Start Date*: 2008-11-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Nalmefene Efficacy Study II: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) ES (Completed) IT (Completed) BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 23 18:34:55 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA